Data in pharma operations with Ashraf Radwan

Episode overview

Ashraf Radwan joins Pharma Republic for a conversation about data in pharma operations. The episode explores career change, commercial analytics, regional data limitations, pharma digital operations, CRM maturity, and why generative AI is becoming a career advantage.

For Revosuite, this episode connects directly to a core belief: commercial operations improve when leaders can see useful signals while the work is still happening.

Why it matters

Pharma teams often make decisions with delayed sales outcomes and incomplete field context. Better data discipline helps leaders understand what is happening across markets, teams, and customer segments before plans drift too far from reality.

Career evolution and embracing change

Stepping out of the comfort zone: Ashraf's career spans several roles, starting as a medical representative in 1994, moving into marketing, and later taking on strategy and consulting work. A key turning point came when he helped launch Viagra, a product that did not fit the classic ethical pharma model and behaved more like a fast-moving consumer good. That experience pushed him to use data analytics to understand consumers, pharmacies, and behavior outside the traditional doctor-led model. 05:08Opens in a new window

The value of consulting: Leaving pharma to start a consulting firm in 2006 taught him the hard way about business sustainability. Unlike a pharma brand that can build long-term momentum, consulting required constantly finding new clients and starting again. That shaped how he later assessed sustainability, business models, and mergers and acquisitions. 15:04Opens in a new window

The power and challenge of data in pharma

Global versus regional data use: Ashraf describes a clear gap between global pharma decision-making and regional operations. Globally, companies invest heavily in R&D using deep data from multiple providers. In markets such as MENA, the data used by commercial teams is often narrower, relying mostly on sales figures and CRM inputs. 18:38Opens in a new window

The struggle to scale: Some local or regional pharma companies say they operate in dozens of countries, but the numbers may show that most revenue still comes from only a few core markets. Expansion requires data on new markets, tender business, distributor quality, and greenfield investment, yet many companies remain focused on short-term profit. 23:07Opens in a new window

The data-sharing bottleneck: One reason MENA lags behind Europe and the US in data analytics is limited data sharing. In more mature data ecosystems, anonymized patient data, insurance claims, and hospital records can support deeper analysis. In the region, authorities and institutions are more hesitant to share data, which limits market understanding and outcome analysis. 37:31Opens in a new window

Digital transformation and advice for the future

CRM is essential but needs to evolve: CRM should do more than count visits. Ashraf argues it should connect with broader business intelligence and help leaders ask sharper questions, including whether mature brands still deserve the same marketing spend simply because the organization has always spent that way. 34:07Opens in a new window

Advice for the next generation: Ashraf's advice for medical representatives and young professionals is to educate themselves aggressively on generative AI and advanced data analytics. AI tools can now complete in hours work that once took weeks, and professionals who master them will move faster than those who rely on outdated methods. 40:07Opens in a new window